Key TakeawaysAbbVie reduced its current quarter outlook related to costs from its acquisition of ImmunoGen.The drug maker announced the $10.1 billion purchase in November, giving it access to ImmunoGen's key ovarian cancer treatment.AbbVie reiterated its full-year outlook, taking into account effects of its purchase of Immunogen and pending acquisition of Cerevel Therapeutics.Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.AbbVie red ...

AbbVie Inc.’s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The company said it now expects first-quarter per-share earnings to range from $2.26 to $2.30, down from prior guidance of $2.30 to $2.34, including a 4 cent per share dilutive impact from the Immunogen deal. AbbVie announced the $10.1 billion all-cash deal for Immunogen in November, that includes ImmunoGen’s antibo ...

Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations AbbVie ...

If you're looking to generate passive income in the new year, there are plenty of ways to do so that don't involve starting a second job or freelance gig. As you work toward your short-term and long-term financial goals, investing is one of many ways you can grow wealth with time.Dividend stocks can help you build your passive income streams, because you can benefit not just from the share price performance of the business, but from regular (usually quarterly) dividend distributions. There are dividend stoc ...

There are thousands of drugs on the market, and there are thousands more that are no longer in use. However, none has been more successful in terms of sales than AbbVie's (ABBV -0.41%) Humira. That's why investors were rightly concerned when the immunology medicine ran out of patent exclusivity in the U.S. last year. AbbVie's CEO, Rick Gonzalez, called it the "largest loss of exclusivity event" in the history of the industry.However, AbbVie saw this headwind coming from a mile away. Though its sales are dec ...

父亲的退休规划 - 父亲出售了他在欧洲繁荣的企业，获得了100万美元以上的收入，为他应得的退休铺平了道路[1] - 父亲现在向我寻求帮助，规划退休计划，并管理出售收入，以通过投资收入维持生活方式[2] - 尽管我自己的退休还有30多年，我的投资重点更倾向于资本增值而不是高收益投资组合，但我决定帮助父亲进行这一重要的过渡[3] 退休规划关键特征 - 退休规划的关键特征应包括：持久的企业、强劲的资产负债表、高质量的非周期性收入、安全且增长的股息[6] - 成功的退休规划应侧重于：分散投资、足够的股息增长以超过通货膨胀、减少股息削减的风险、根据年龄调整资本增值[11] - 在接近退休时，医疗保险是一个关键因素，尽管父亲将自动获得政府提供的全额医疗保险，但对于需要考虑这一费用的美国投资者来说，情况则大不相同[12] 投资组合分析 - 该样本投资组合具有5%的收益率，相当于税前50133美元的年收入，通过手动挑选个别股票，我们在股息增长和当前收益之间取得了良好的平衡[24] - 投资组合的5年股息增长率为7.7%，预计这一趋势将持续下去。前3年的EPS增长预期为6.1%，该投资组合可能提供高达11.1%的税前回报，略低于近年来标普500指数的表现[25] - 投资组合中的持股在各个行业中进行了精心分散，涵盖了具有持久模型的企业，所有这些企业的股息率至少为2%或更高。除了Ares Capital外，每个持有的股息增长率都不低于3%[26] 优质股票推荐 - Schwab美国股息权益ETF是追求可持续和高质量股息的投资者的首选选择，拥有104个持股和平均市盈率为16.1倍，是一个估值友好的选择，以获取股息增长。ETF的ROE高达37.3%，表明其潜在股票的高质量[28] - Enterprise Products Partners是一家中游基础设施提供商，通过其超过5万英里的管道网络产生稳定的收入，提供7.85%的诱人分配收益，支持强大的1.7倍分配覆盖率[29] - Realty Income，也被称为“月度股息公司”，是一家'A-'评级的房地产投资信托公司，具有非常稳定的商业模式，重点放在具有三重净租赁的单一租户物业上[30] - Allianz是投资组合中唯一的欧洲股票，总部位于德国慕尼黑，专门从事保险和资产管理，提供4.7%的股息收益率，预计未来3年EPS将增长约6.3%[31] - AbbVie成立于2013年，是从Abbott Laboratories (ABT)分拆出来的独立制药公司，拥有3.6%的股息收益率，过去5年的显着增长为8.7%，预计未来3年的EPS增长为6.5%[32] - NextEra Energy是世界上最大的公用事业公司，致力于清洁能源，预计EPS增长率为7.5%，股息收益率为3.32%，预计未来几年将以高个位数的速度增长[33] - Ares Capital是美国最大的商业发展公司，提供小型和中型企业的债务融资，收入主要来自利息和费用，预计未来3年的增长率为0.5%，但其9.6%的股息收益率仍然吸引人[34]

Investors know the phrase “let your winners run,” but it’s easier said than done. The temptation to take profits off the table is often too great to ignore. By doing so, however, we run the risk of undercutting our portfolio returns. Having said that, you can’t go wrong with these stocks that just hit 52-week highs. There are quite a few winning stocks at 52-week highs that investors should continue to let run. The following three stocks may be at new peaks, but they have plenty of room to move higher still ...

股息贵族变动 - Kiplinger发布了2024年标普500股息贵族的幻灯片展示[1] - 标普道琼斯指数每年一月重新平衡标普500股息贵族，目前有67家公司[2] - 2024年1月宣布了两家公司的变动：Walgreens Boots Alliance (WBA)被剔除，Fastenal (FAST)被添加[3][4] - 过去一年内，股息贵族发生了其他变动，包括V.F. Corporation (VFC)被剔除，Kenvue (KVUE)被添加[5] 股息贵族投资 - 股息贵族是过去几十年来最好的股息股票之一，是长期投资组合中的不错选择[6] - 大多数股息贵族公司的股价过高，难以证明其薄利股息的合理性[7] - 在十大股息贵族中，有四家公司的年度股息超过了其单股价格，包括Realty Income Corporation (O)、Amcor plc (AMCR)、Franklin Resources, Inc. (BEN)和Kenvue Inc[8] - 另外六家公司可能很快加入到理想的四家公司中[9] 股息贵族预测 - 分析师预测2025年2月，十大股息贵族的净收益将在11.95%至40.69%之间[11] - 2024-2025年的估计股息回报数据显示了十大高股息股票的预期收益[12]-[20] - 五家最低价高股息股票的预期收益比十大股息贵族整体预期收益高出25.31%[31] - 四家十大股息贵族公司的股价低于从$1K投资中获得的年度股息，这些公司的最近价格和公平价格进行了比较[38]

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the option to explore the applicability of Calibr-Skaggs' sCAR-T platform in autoimmune diseases Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches LA JOLLA, Calif., Feb. 6, 2024 /PRNewswire/ -- The Calibr-Skaggs Institute for Innovative Med ...

AbbVie股票表现 - AbbVie (ABBV) 是近期 Zacks.com 访问者最关注的股票之一[1] - 过去一个月，AbbVie的股价上涨了 +6.1%，而 Zacks S&P 500 综合指数上涨了 +5.3%[2] - AbbVie 所属的 Zacks 大型药品行业上涨了 4.6%[2] 公司盈利预期 - AbbVie 当前季度预计每股盈利为 $2.41，较去年同期下降了 -2%[5] - 本财年，AbbVie 的一致盈利预期为 $11.18，较去年同期增长了 +0.6%[6] - 下一财年，AbbVie 的一致盈利预期为 $12.26，较去年同期增长了 +9.7%[7] 公司评级和评分 - AbbVie 的 Zacks Rank 评级为 3 (持有)[8] - AbbVie 在过去四个季度中均超过了一致盈利预期，同时也每次超过了一致营收预期[13] - AbbVie 的 Zacks Value Style Score 为 B，表明其相对同行公司交易时处于折价状态[17]